Dr. Hallenbeck is the Founder, President and Chief Scientific Officer. He is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry with expertise in all phases of cancer immuno-therapeutics R&D. As the sole founder of Neotropix, he raised $30M in VC, then successfully led SVV (NTX-001) through IND approval, and completed several Phase I/II clinical trials, establishing an excellent safety record & compelling evidence of efficacy.
This speaker appears at this event:
Paul Hallenbeck, PhD
President and Chief Scientific Officer, Seneca Therapeutics